

Príomhoifigeach Cliniciúil Oifig an Phríomhoifigigh Cliniciúil

Ospidéal Dr Steevens, Lána Steevens Baile Átha Cliath 8, D08 W2A8

Chief Clinical Officer Office of the Chief Clinical Officer

Dr Steevens Hospital, Steevens Lane t 01 635 2000 Dublin 8, D08 W2A8

www.hse.ie @hselive

e cco@hse.ie

BY EMAIL ONLY

Deputy Pádraig O'Sullivan Dáil Éireann Leinster House Kildare Street Dublin 2

12th January 2023

58291/22- Deputy Pádraig O'Sullivan- To ask the Minister for Health when the emergency authorisation process for Covid-19 treatments closed; and if he will make a statement on the matter.

Dear Deputy O'Sullivan,

Thank you for your representation.

The HSE is committed to providing access to as many medicines as possible, in as timely a fashion as possible, from the resources available (provided) to it. HSE decisions on which medicines are reimbursed by the taxpayer are made on objective, scientific and economic grounds.

The pricing and reimbursement of COVID-19 anti-viral agents is now incorporated into the well-established HSE medicines reimbursement process since 2022. The principles underpinning the assessment of new medicines are outlined in the framework agreement on the supply and pricing of medicines (IPHA Agreement 1/10/2021). The legislative basis underpinning the process includes the Health (Pricing and Supply of Medical Goods) Act 2013. The HSE robustly assesses applications for pricing and reimbursement to make sure that it can stretch available resources as far as possible and to deliver the best value in relation to each medicine and ultimately more medicines to Irish citizens and patients.

I hope this provides you with assistance.

Yours sincerely

Sharon Hayden General Manager

Office of the CCO